Stage and Site Specific Sensitivity of Fecal Immunochemical Tests for Large Advanced Adenomas and Cancers

2015 Fiscal Year Final Research Report

• Project/Area Number: 25460785
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Epidemiology and preventive medicine
• Research Institution: National Cancer Center Japan
• Principal Investigator: Matsuda Takahisa 国立研究開発法人国立がん研究センター, 中央病院, 検診センター長 (30508049)
• Co-Investigator(Kenkyū-buntansha): KAKUGAWA Yasuo 国立がん研究センター中央病院, 内視鏡科, 医長 (00537889) ; OONO Yasuhiro 国立がん研究センター東病院, 消化管内視鏡科, 医員 (50602025)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 大腸癌 / スクリーニング / 便潜血検査 / 診断感度 / 部位別検討

Outline of Final Research Achievements

Although fecal immunochemical test (FIT) has been widely adopted in many population based colorectal cancer (CRC) screening programs, its stage- and anatomical site-specific sensitivity for advanced colorectal neoplasms remains unclear. A total of 333 subjects [mean age: 63.9years, 176 males (52.9%)]with advanced neoplasms were prospectively enrolled. Of them, 219 had cancerous lesions [Tis (carcinoma in situ):54, T1:48, and T2 to T4:117]. The sensitivity of FIT for advanced adenoma, Tis, T1, and T2-4 cancers were 45.6% (36.3-55.2%), 48.1% (34.5-62.0%), 77.1% (62.3-87.5%), and 91.5% (84.5-95.6%), respectively. FIT had significantly lower sensitivity for proximally located lesions than distal ones in advanced adenomas (34.8% vs. 60.4%, P=0.008), cancers (64.5% vs. 84.6%, P=0.001), and invasive cancers (76.0% vs. 92.2%, P=0.006). FIT had significantly lower sensitivity for proximal located and early cancerous lesions.

Free Research Field

大腸癌スクリーニング・サーベイランス